The ATRiUM prospective clinical trial – combining cytotoxic agents with DDR inhibitors.
This trial examines the use of Gemcitabine as a sensitizer for ATR inhibition in the treatment of selected patients with pancreatic cancer.
Using model based, dual agent clinical trial design. This trial should overcome the current “challenges” of combining cytotoxic agents with DDR inhibitors. Will increase scientific understanding of the interplay between chemotherapy, DDR modulating agents and DDR/DDR combos, providing both AZD6738 (ATRi) and broader portfolio impact.
The Mark Foundation Institute for Integrated Cancer Medicine (MFICM) at the University of Cambridge aims to revolutionise cancer care by affecting patients along their treatment pathway.
